A new study suggests that the immune checkpoint inhibitor, durvalumab, may offer new treatment options for patients living with small cell lung cancer (SCLC).

With most lung cancers in India diagnosed at advanced stages, experts say low-dose CT screening for high-risk groups like ...

The National Football League Alumni Association (NFL Alumni) and the Centers for Disease Control and Prevention (CDC) Division of Cancer Prevention and Control have expanded the "GEAR UP Against ...

Breast cancer screening based on individual risk rather than annual screening is safe, effective and preferred by patients, ...

A new study suggests that the immune checkpoint inhibitor, durvalumab, may offer new treatment options for patients ...

Revolution Medicines shows RAS drug optimism with phase 3 catalysts, early-stage valuation, buyout chatter, and competition ...

Reversing the standard approved dose levels of nivolumab (Opdivo) and ipilimumab (Yervoy) in metastatic melanoma led to less ...

In return for the rights to YL201 outside China, MediLink will receive upfront and potential near-term milestone payments ...

Merck begins phase 3 KANDLELIT-007 trial of calderasib in combo Keytruda QLEX in certain patients with advanced NSCLC: Rahway, New Jersey Friday, January 9, 2026, 15:00 Hrs [IST] ...

Cancer cells employ a variety of strategies to evade the immune system, and modern immunotherapies aim precisely at these ...

RVMD stays a Strong Buy as RAS inhibitor trials advance; phase 3 RASolute-302 is a key 2026 catalyst. Read the latest ...

Proteomic mass spectrometry can identify key biomarkers in IPF, aiding in diagnosis and prognosis despite the disease's ...